Evaluation of pulmonary hypertension in heart transplant candidates

被引:22
作者
Natale, ME
Piña, IL
机构
[1] Univ Hosp Cleveland, Heart Failure & Transplant Ctr, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Cleveland, OH 44106 USA
关键词
D O I
10.1097/00001573-200303000-00012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Assessment of the pulmonary circulation and right ventricular function is a cornerstone in the evaluation of the patient as a potential heart transplant recipient. The importance of pulmonary hypertension is linked to outcomes in the posttransplant period. Preoperative pulmonary vascular resistance is an independent risk factor for early death after heart transplantation. Pulmonary hypertension can be classified as reversible, or irreversible if not rapidly responsive to pharmacologic maneuvers. However, in most patients, the major component is likely to reverse with vasodilators, because of the central role played by the endothelium in the control of pulmonary vascular tone. To discriminate between patients with reversible and irreversible pulmonary hypertension, provocative therapies are used, and baseline and the postprovocation hemodynamic parameters are measured. To date, there is no reliable hemodynamic threshold beyond which right ventricular failure is certain to occur, nor are there values below which right ventricular failure is always avoidable. Because of this uncertainty, it becomes clear that only through careful preoperative assessment can this life-threatening condition be recognized preoperatively and, hence, managed in the posttransplant recovery period. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:136 / 140
页数:5
相关论文
共 42 条
[1]   PULMONARY-HYPERTENSION PREDICTS MORTALITY AND MORBIDITY IN PATIENTS WITH DILATED CARDIOMYOPATHY [J].
ABRAMSON, SV ;
BURKE, JF ;
KELLY, JJ ;
KITCHEN, JG ;
DOUGHERTY, MJ ;
YIH, DF ;
MCGEEHIN, FC ;
SHUCK, JW ;
PHIAMBOLIS, TP .
ANNALS OF INTERNAL MEDICINE, 1992, 116 (11) :888-895
[2]   Inhaled nitric oxide as a preoperative test (INOP Test I) - The INOP Test Study Group [J].
Balzer, DT ;
Kort, HW ;
Day, RW ;
Corneli, HM ;
Kovalchin, JP ;
Cannon, BC ;
Kaine, SF ;
Ivy, DD ;
Webber, SA ;
Rothman, A ;
Ross, RD ;
Aggarwal, S ;
Takahashi, M ;
Waldman, JD .
CIRCULATION, 2002, 106 (13) :I76-I81
[3]   INHALED NITRIC-OXIDE LEADING TO PULMONARY-EDEMA IN STABLE SEVERE HEART-FAILURE [J].
BOCCHI, EA ;
BACAL, F ;
AULER, JOC ;
CARMONE, MJD ;
BELLOTTI, G ;
PILEGGI, F .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 74 (01) :70-72
[4]  
BOURGE RC, 1993, J HEART LUNG TRANSPL, V12, P549
[5]   β-adrenergic receptor blockade in chronic heart failure [J].
Bristow, MR .
CIRCULATION, 2000, 101 (05) :558-569
[6]   Effect of nitroglycerin in patients with increased pulmonary vascular resistance undergoing cardiac transplantation [J].
Bundgaard, H ;
Boesgaard, S ;
Mortensen, SA ;
Arendrup, H ;
Aldershvile, J .
SCANDINAVIAN CARDIOVASCULAR JOURNAL, 1997, 31 (06) :339-342
[7]   A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST) [J].
Califf, RM ;
Adams, KF ;
McKenna, WJ ;
Gheorghiade, M ;
Uretsky, BF ;
McNulty, SE ;
Darius, H ;
Schulman, K ;
Zannad, F ;
HandbergThurmond, E ;
Harrell, FE ;
Wheeler, W ;
SolerSoler, J ;
Swedberg, K .
AMERICAN HEART JOURNAL, 1997, 134 (01) :44-54
[8]   Lisinopril attenuates acute hypoxic pulmonary vasoconstriction in humans [J].
Cargill, RI ;
Lipworth, BJ .
CHEST, 1996, 109 (02) :424-429
[9]  
CHEN JM, 1997, TRANSPLANTATION REPL, P177
[10]  
COHN JN, 1983, J AM COLL CARDIOL, V2, P755